Xyzal Dosage/Direction for Use

The film-coated tablet must be taken orally, swallowed whole with liquid and may be taken with or without food. It is recommended to take the daily dose in one single intake.
Duration of use: Intermittent allergic rhinitis (symptoms <4 days/week or during less than 4 weeks a year) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear.
In case of persistent allergic rhinitis (symptoms >4 days/week or for more than 4 weeks a year), continuous therapy can be proposed to the patient during the period of exposure to allergens.
There is clinical experience with the use of levocetirizine for treatment periods of at least 6 months. In chronic urticaria and chronic allergic rhinitis, there is clinical experience of use of cetirizine (racemate) for up to one year.
Adults and adolescents 12 years and above: The daily recommended dose is 5 mg (1 film-coated tablet).
Children: Children aged less than 2 years: The administration of levocetirizine to infants and toddlers aged less than 2 years is not recommended (see Precautions).
Children aged 2 to 6 years: For children aged 2 to 6 years no adjusted dosage is possible with the film-coated tablet formulation.
Children aged 6 to 12 years: The daily recommended dose is 5 mg (1 film-coated tablet).
Elderly: Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Renal impairment as follows).
Renal impairment: The dosing intervals must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CLcr) in mL/min is needed. The CLcr (mL/min) may be estimated from serum creatinine (mg/dL) determination using the following formula: see equation and table.


Click on icon to see table/diagram/image




Click on icon to see table/diagram/image


Hepatic impairment: No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see Renal impairment in the previous text).
Route of administration: For oral use.